On November 3rd, Washington DC will be voting on Initiative 81 to make the enforcement of laws against natural plant medicines among the lowest law enforcement priorities.
Thank you for visiting Psychstocks.com an organization that is dedicated to discovering the future leaders of the emerging psychedelic plant medicine industry. Learn about our organization and founder by reading this article.
Following the release of Citron Research’s bullish report on Compass Pathways (CMPS), the stock gained as much as 28.44% to reach a new record high of $47.29 per share, but only finished the day up by 8.91% to $40.10 per share. We believe Andrew Left made a mistake by releasing his report before the open of trading.
On November 3rd, residents of Oregon will vote on Oregon Measure 109, the Psilocybin Mushroom Services Program Initiative of 2020.
NUMI has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
The total gross proceeds from CMPS’s IPO were $146.6 million after sale of additional 1,125,000 ADSs.
CMPS raises $127.5 million at IPO price of $17 per ADS.
Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval
Our friends at the Non-Profit MAPS have successfully raised $30 million through the Capstone Campaign to be used to seek FDA approval of MDMA-assisted psychotherapy for PTSD.
We are excited to announce Numinus Wellness (TSXV: NUMI) as our #1 Favorite Pick of 2020